Advanced search
Publication Cover
Patient Related Outcome Measures Volume 15, 2024 - Issue
Submit an article Journal homepage
78
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cross-Sectional Quantitative Evaluation of a Novel Patient-Reported Outcome Measure in Familial Chylomicronemia Syndrome

T Michelle Brown1 Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USAORCID Iconhttps://orcid.org/0000-0002-4580-805XView further author information
ORCID Icon,
Montserrat Vera-Llonch2 Health Economics & Outcomes Research, Ionis Pharmaceuticals, Carlsbad, CA, USAView further author information
,
Chisom Kanu1 Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USAView further author information
,
Asia Sikora Kessler2 Health Economics & Outcomes Research, Ionis Pharmaceuticals, Carlsbad, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9417-6637View further author information
ORCID Icon,
Aaron Yarlas2 Health Economics & Outcomes Research, Ionis Pharmaceuticals, Carlsbad, CA, USAORCID Iconhttps://orcid.org/0000-0003-4600-259XView further author information
ORCID Icon &
Sheri E Fehnel1 Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USAORCID Iconhttps://orcid.org/0000-0001-8568-0102View further author information
ORCID Icon
Pages 45-59 | Received 23 Sep 2023, Accepted 11 Jan 2024, Published online: 15 Feb 2024

References

  • Regmi M, Rehman A. Familial Hyperchylomicronemia. Syndrome: StatPearls; 2022.
  • Pallazola VA, Sajja A, Derenbecker R, et al. Prevalence of familial chylomicronemia syndrome in a quaternary care center. Eur J Prev Cardiol. 2020;27(19):2276–2278. doi:10.1177/2047487319888054
  • Fox RS, Peipert JD, Vera-Llonch M, et al. PROMIS® and Neuro-QoL TM measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome. Expert Rev Cardiovasc Ther. 2020;18(4):231–238. doi:10.1080/14779072.2020.1748011
  • Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352–362. doi:10.1038/nrendo.2015.26
  • Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther. 2017;15(5):415–423. 20170404. doi:10.1080/14779072.2017.1311786
  • Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898–907 e892. 20180426. doi:10.1016/j.jacl.2018.04.009
  • Davidson D, Slota C, Vera-Llonch M, et al. Development of a novel PRO instrument for use in familial chylomicronemia syndrome. J Patient Rep Outcomes. 2021;5(1):72. 20210811. doi:10.1186/s41687-021-00347-5
  • Food and Drug Administration (FDA). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance.RegulatoryInformation/Guidances/UCM193282.pdf. Accessed February 4, 2020.
  • Food and Drug Administration (FDA). Patient-focused drug development (PFDD) guidance: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. Attachment to guidance 3 discussion document–appendices; 2018. Available from: https://www.fda.gov/media/116277/download. Accessed August 15, 2021.
  • Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) Measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8(2):94–104. doi:10.1111/j.1524-4733.2005.04054.x
  • Cella D, Yount S, Rothrock N, et al. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care. 2007;45(5 Suppl 1):S3–S11. doi:10.1097/01.mlr.0000258615.42478.55
  • Svedlund J, Sjodin I, Dotevall G. GSRS--A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129–134. doi:10.1007/BF01535722
  • Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7(1):75–83. doi:10.1023/a:1008841022998
  • Cohen J. A power primer. Psychol Bull. 1992;112(1):155–159. doi:10.1037//0033-2909.112.1.155
  • Kline P. A Handbook of Test Construction: Introduction to Psychometric Design. New York: Methuen & Co; 1986.
  • Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16(3):297–334. doi:10.1007/bf02310555
  • Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. 2nd ed. New York: Oxford University Press; 1995.
  • Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, N.J: L. Erlbaum Associates; 1988.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.